![](https://investorshub.advfn.com/uicon/563962.png?cb=1562358883)
Tuesday, April 05, 2022 6:51:01 PM
Enzolytics, a Texas-based maker of monoclonal antibody drugs, has inked a deal with Samsung Biologics to support and manufacture its investigational new drug treatments for HIV and COVID-19.
Samsung Biologics will produce a stable cell line and other materials for Enzolytics' monoclonal antibodies from facilities in San Francisco and Incheon, South Korea. (Samsung Biologics)
October 7, 2021
https://www.fiercepharma.com/manufacturing/enzolytics-inks-cmo-deal-samsung-for-covid-19-hiv-drugs
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM